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ABSTRACT
MicroRNAs are a family of small, non-coding RNAs which regulate gene expression at 
post-transcriptional level. These ncRNAs influence cellular physiology by directly interacting 
with target gene transcripts. miRNA expression pattern can be correlated with cancer types, 
stages and other clinical variables. Therefore miRNA profiling can be used as a tool for cancer 
diagnosis and prognosis in almost all aspects of cancer biology such as proliferation, apoptosis, 
invasion and angiogenesis. Our study aims at identification of novel miRNA-mRNA target pairs 
that are hypothesized to play role in fibrosarcoma through an interaction map analysis from 
microarray data followed by experimental validation of selected pair of mRNA and miRNA by 
qRT-PCR. The target interaction map analysis revealed one novel target pair i.e. hsa-miR-429-
p15PAF which can be potential therapeutic target in fibrosarcoma.
Keywords: miRNAs, fibrosarcoma, metastasis, non-coding RNAs 
1INTRODUCTION 
Cancer is a complex disease that involves an array of changes at genetic & epigenetic 
levels and is characterized by uncontrolled cell growth. It affects millions of lives and also 
causes many deaths over the years. It consists of group of cells and is of more than 200 different 
types based on where they originate in the body. As cells are basic units of life so all organisms 
are composed of one or more cells. When the body requires cells, they start to divide to produce 
a number of cells in order to fulfill the requirement of the body. But when these cells keep 
dividing uncontrollably they create a mass of tissue. This mass of extra tissue is called as tumor 
which can be formed in all kinds of tissue and can be benign or malignant. Malignant tumors are 
called cancer. They can be of different types of based on their organ of origin like breast cancer, 
skin cancer, lung cancer, colon cancer, prostate cancer etc.
Sarcomas are the mesenchymal malignancies (D’Angelo et al., 2014) arising from bone, 
cartilage or connective tissues. Adult fibrosarcoma is defined by World Health Organization 
(Zambo and Vesely, 2014) as malignant neoplasm composed of fibroblasts having variable 
collagen production. It is also defined by Schultze et al as a tumor originating from mesenchymal 
cell which is composed of malignant fibroblasts with a collagen background (Schultze et al., 
1998). It can occur as a soft-tissue mass or as a primary or secondary bone tumor. In the past 
though fibrosarcoma was diagnosed frequently but now it is more reliably distinguished 
histologically from similar lesions such as desmoid tumors, malignant fibrous histiocytoma, 
malignant schwannoma and high-grade osteosarcoma.
There are generally two forms of this disease:
 Infantile or congenital fibrosarcoma:  A type of soft tissue sarcoma which is most commonly 
found in children less than one year of age (Ainsworth et al., 2014). At birth or shortly after 
birth, it presents as a rapidly growing mass. This form of fibrosarcoma is usually very slow-
growing and also tends to be more benign than fibrosarcoma in older children, which behaves 
more like the type found in adults.
2 Adult form fibrosarcoma: The adult form of this disease can occur in older children and in 
adolescents, roughly between the ages of 10 and 15. It is more aggressive than the infantile form 
and involves more complex treatment.
     Though the exact cause of fibrosarcoma and other soft tissue tumors is not entirely 
known, however, studies indicate that genetic alterations may play a role. Limited studies have 
also shown a possible link between soft tissue sarcomas and the development of other types of 
cancer. A chromosomal rearrangement has also been found in some fibrosarcomas.
     Though sarcoma may arise virtually anywhere, but the extremity is the most common 
primary site. During metastasis the most common site to which the fibrosarcoma spreads is the 
lungs. Of patients with extremity sarcoma, approximately 20% will have isolated pulmonary 
metastatic disease at some point in the course of their disease. Genetic mutation is the main 
cause of tumerogenesis and metastasis in soft tissue sarcoma. As mechanism for controlling 
metastasis are poorly understood so it is important to understand the molecular mechanism 
involved in primary tumor cell invasion and its spread to distant sites and thus to identify new 
molecular targets for cancer therapies.
Till date hundreds of miRNA have been identified in mammals some of which are 
expressed in a tissue specific and developmental stage specific way. In recent times much 
progress has been done in discovery of this regulatory RNA phenomenon. miRNAs generally 
interact with the target mRNAs (Than et al., 2013) with only partial or imperfect 
complementarity which causes either mRNA degradation or translational inhibition and thus can 
regulate the expression of target genes negatively. Thus up-regulation and down-regulation of 
miRNA has been seen to play a role in cancer progression.
In normal cellular development miRNA play essential roles, but functionally it may act 
either as oncogenes or tumor suppressors (Zhang et al., 2007) targeting analogous or tumor 
suppressor genes. miRNAs have the capacity to target gene transcripts directly and influence 
cellular physiology which is found to be involved in cancer etiology.
Though metastasis is well understood in cancers of epithelial origin, but it is not clearly 
understood in cancers of mesenchymal origin (sarcoma). So from microarray analysis we try to 
screen out probable genes responsible for metastasis in fibrosarcoma. In our present study, 1068 
3differentially expressed genes were obtained between Myxofibrosarcoma and the control normal 
fat samples. Of these 558 genes were up-regulated and 510 genes were down-regulated. 
Similarly 78 miRNAs were found to be differentially expressed in Myxofibrosarcoma and the 
control normal fat samples. Of these 27 were down-regulated and 51 were up-regulated. So from 
558 up-regulated genes and 27 down-regulated miRNAs we wanted to check expression of 
p15PAF which is found to be targeted by miR-429 according to Magia2 interaction map analysis.
4REVIEW OF LITERATURE
Tumorigenesis is a multistep process wherein the normal cell is transformed into a malignant 
cell. The uncontrolled proliferation of these malignant cells by ignoring the normal rules of cell 
division results in disease known as cancer. Cancer is thus an abnormal condition which mainly 
results due to changes or mutation in the microenvironment of the cell. Cancer cell have the 
ability to spread into other body parts of the body and colonize and grow at the secondary sites. 
This process is known as metastasis. In 90% cases, metastasis is the main cause of death in 
patients suffering from cancer.          
Cancer can be classified on the basis of where they originate or on the basis of location 
where they develop initially. Thus on the basis of tissues of origin cancers are of the following 
types:
Carcinoma: Cancer which arise from the covering cells of external and internal body surface 
called epithelial cells and these are the most common type of cancer.
Sarcoma: Cancer which arise from mesenchymal cells which are found in supporting tissues of 
the body for example  bone, cartilage, fat, conective tissue and muscle.
Lymphoma: Cancers that  arise in lymph node and tissues of body’s immune system.
Leukomia: Cancers in which bone marrow is not allowed to form RBCs, WBCs and platelets 
and thus it is also called blood cancer (Appelbaum, 2011). WBC protects body from infection, 
RBCs help in oxygen transport and mainly prevent anemia and platelets help in clotting of blood 
at the time of injury.
Myeloma: This type of cancer is found to grow in plasma cells of bone marrow (Kyle and 
Rajkumar, 2009). It is of 2 types that is Plasmacytoma in which myloma cells found to 
accumulate in a sinle bone thus forming a tumor and second one is multiple myeloma where 
myeloma cells by accumulating in many bone produce many bone tumors.
Blastoma: It originates from immature precursor cells or embryonic tissue. It is found to be 
more common in children than in adult.
5SARCOMA
These are the cancers of mesenchymal origin. In human sarcoma is quite rare. Majority of 
death in sarcoma is also due to metastasis. Here mainly 2 types of metastasis are there like nodal 
metastasis and distant metastasis. In nodal metastasis the cancer cell move to distant body parts 
through lymph node which is very rare one and other one is distant metastasis which generally 
spread to lungs.
Types of sarcoma:
1) Soft tissue sarcomas: These arise from soft tissues for e.g. muscles, fat, nerves, blood vessels 
and fibrous tissue. About 80% of sarcoma arises in soft tissues. According to WHO soft tissue 
sarcoma occupies 23rd position among all cancer on the basis of occurrence.
2) Osteosarcoma: It is otherwise called as osseous sarcoma which starts in bone. In comparison 
with benign bone tumor and secondary cancer, osteosarcomas are much less common. It 
occupies 27th position among all cancer on the basis of occurrence. 
    Again based on the cell type which makes up the cancer, sarcomas are subdivided into 
different types (Table 1).
Table 1. Subtypes of sarcoma and their origin:
Subtypes of sarcoma Type of cells forming tumor 
Angiosarcoma Blood or lymphatic vessel
Chondrosarcoma Cartilage cells 
Ewing’s sarcoma Soft tissue or Bone 
Fibrosarcoma Fibrous tissue 
Gastrointestinal stromal tumor tract Gastrointestinal tract 
Leiomyosarcoma Smooth muscles of abdominal and pelvic organs 
6Liposarcoma Fat tissue 
Malignant peripheral nerve sheath tumor Nerve and Spinal cord
Osteosarcoma Bone 
Pleomorphic sarcoma Limb or abdomen 
Rahbdomyosarcoma Skeletal muscle 
Synovial sarcoma Often seen in young adults in different locations
Fibrosarcoma:
This is a tumor which develops from fibrous tissue which is mesenchymal in origin and is 
formed of fibroblasts, which are histologycally predominant cells (Loh et al. 2002). 
Fibrosarcomas form solid tumors. They may be of different grades according to the degrees of 
differentiation: low grade which is differentiated, intermediate grade and high grade (anaplastic). 
Depending on this differentiation, the tumour cells may resemble mature spindle-shaped 
fibroblasts which secrete collagen with rare mitoses. High grade mostly show metastasis that is 
they have the capacity to enter into local tissues thus spreading tumors to different body parts. 
Majority of death in fibrosarcoma is mainly due to metastasis which is poorly diagnosed or 
poorly understood in fibrosarcoma unlike in carcinomas.
METASTASIS 
It is a process in which malignant cells move from primary tumor to distant organs 
through the lymphatic or haematogenous circulatory system. About 10% of deaths in patients of
cancer occur due to primary tumor but 90% of death is due to movement of cancer cells (Leber 
and Efferth, 2009).
Metastatic sites  
The sites where the primary tumor will spread and form a secondary malignant tumor is 
called site of metastasis (Table 2.). The determination of these metastatic sites by the tumor cells 
7in primary site is called organ selectivity. For organ selectivity 2 theories are there, first one is 
mechanistic theory in which organ is determined by pattern of blood flow and the other one is 
seed and soil theory (Fokas et al. 2007) that is spreading will occur to that site where there is 
fertile environment so that compatible tumor cells can grow (Nguyen et al. 2009).
Table 2. Different sites of metastasis
Primary tumor Common distant sites
Breast adenocarcinoma Brain, Bone, Adrenal
Prostate adenocarcinoma Bone
Lung small cell carcinoma Bone ,Liver, Brain
Skin cutaneous melanoma Brain ,Liver
Testis carcinoma Liver
Bladder carcinoma Brain
Neuroblastoma Liver ,Adrenal
.
Steps of metastasis
Metastasis is a multi step process which involves the following steps (Fig 1) 
1) Local invasion
2) Intravasation 
3) Transport through circulation
4) Extravagation
5) Formation of micro-metastasis
6) Colonization
Fig 1: Different stages
Local invasion: Through the basement membrane barrier
Intravasation: Passing through
In this step cancer cell will obtain different properties like invasiveness and cell motility. Due to 
this new property it can enter into the circulatory system.
Transport through circulation
tissue, it continues its journey through blood or lymph
many cancer cells will die or be 
a first set of capillary and form microthrombi. 
Extravasation: Finally in this step cancer cell
move into the tissue (Stoletov, 2010)
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of metastasis 
, in-situ tumor breaks.
wall of capillaries the tumor cell move into circulatory system. 
: Until and unless cancer cell will attach to a solid supporting 
. Due to hostile condition at this 
destroyed and the remaining surviving cancer cell
s will attach themselves to the secondary site and
.
stage 
will attach to 
9Formation of micrometastasis: After extravasation, the cancer cells have the capacity to 
reactivate cell proliferation pathways and finally a small tumor mass is formed at the secondary 
site.
Colonization: The new environment provides different factors for the survival and proliferation 
of cancer cell so as to colonize. This step is a challenging and complex one as the cancer cells 
have to adopt themselves to a completely new environment.
Molecules involved in metastasis:
For metastasis the tumor cell first have to acquire metastatic property which need a number 
of changes allowing intravasation and extravasation as well as colonization. A cell differentiated 
circuit is activated called EMT (Yilmaz and Christofori, 2009) that is epithelial to mesenchymal 
transition by promoting expression of a number of EMT permissive transcription factors. These 
cancer cells get the properties of mesenchymal cells that are invasiveness and motility. This 
process of EMT occurs mainly in cancers of epithelial origin. The different molecules involved 
are-
1) CAMs (cell-cell adhesion molecule) - It binds cells to surrounding tissue (Schlesinger and 
Bendas, 2014). They involve a protein called cadherin which help in metastasis and is seen in all 
epithelial cells. Generally in normal cells E-cadherin functions as a bridge between adjacent cells 
but in epithelial cancers function of E-cadherin is lost due to which it plays an important role in 
metastatic property (Onder et al., 2008).
2) Integrin- It is a protein having role in tissue invasion, angiogenesis, cell adhesion, migration, 
control of cell differentiation, proliferation and survival of cancer cells (Albelda, 1993).
3) MMPs (Matrix metallo proteinases) – Its increasing expression has role in successful 
colonization (Chambers and Matrisian, 1997). 
Metastasis is one of the primary reasons for death in cancer patients. Recent reports suggest that 
microRNA also play an important role in regulating genes involved in different steps of 
metastasis.
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MicroRNA:
They are small noncoding RNAs which control gene expression post transcriptionally 
through translational repression or degradation of mRNA (Cai et al. 2009). Recent reports
suggest that microRNAs (miRNAs) play an important role in initiation and progression of 
different types of cancers. They are found to regulate different processes like cell differentiation, 
growth and apoptosis (Esquela and slack, 2006). For various diseases miRNAs are found to be 
biomarkers and potential therapeutic targets. In cancer cells deregulation of miRNA occurs by 
different mechanisms like amplification, deletion, mutation and epigenetic silencing (Garzon et 
al. 2009). 
Maturation of miRNAs:
Primary miRNA (pri-miRNA) precursor molecule is produced by the transcription of 
miRNA (Fig 2). It undergoes cleavage producing precursor miRNA (pre-miRNA) which is 
cleaved to produce miRNA duplex in cytoplasm which contains mature miRNA. Then 
unwinding of duplex occurs as a result of which mature miRNA are released and assemble with 
RISC complex. These mature miRNA then direct gene silencing through translational repression 
or mRNA cleavage.
The intergenic miRNAs are transcribed with the help of either RNA polymerase II or III, 
(Fig 3). Pri-miRNA molecule is produced, which with the help of microprocessor complex made 
up of DGCR8 and Drosha give rise to pre-miRNA which with the help of nucleocytoplasmic 
transporter Exportin-5 and Ran-GTP is exported to the cytoplasm. Intronic miRNAs are
transcribed with the help of RNA polymerase II forming pre-miRNA. From this pre-miRNA the 
miRNA sequence is removed in order to generate a Mirtron which is exported out of the nucleus. 
Fig 2: microRNA maturation and function
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Fig 3: Different nuclear component taking part in microRNA biogenesis
MicroRNA targeting:
MicroRNAs generally target the mRNA for post transcriptional repression and for that it 
obeys certain rules. According to the rule
Watson and Crick pairing towards 5’ region of miRNA 
transcriptional repression miRNA
helpful in predicting miRNA target which indicate
in specifying targeting. One third of human gene
order to maintain their pairing with that of
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, pairing of miRNA and mRNA need
(Lewis et al.,
s bind to 3’ UTR of mRNA. Seed matching is not
s that different other characteristics also help 
s are found to be under selective pressure in 
the seed region of miRNA. Mainly 5’ UTR of
s a conserved
2003). For post 
always
the
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miRNA take part in binding but sometime in addition with 5’ UTR, 3’ UTR and open reading 
frame also take part in binding.
miRNA expression profiling in sarcomas
miRNA expression profiling in sarcomas has helped in the monitoring of the expression 
of thousands of miRNAs. Presently more than 1000 miRNAs have been identified in human. In 
different carcinomas, sarcoma and hematologic malignancies, analysis of miRNAs expression
disclosed uniform pattern of specific miRNAs. Due to strong association with cancer some 
miRNAs are also called as oncomiR. For example miR-21 is found to be over expressed in 
gliobalstomas or microRNA 17-92 cluster found to be up-regulated in B cell lymphoma, 
rhadomyosarcoma and liposarcoma. Some miRNA clusters which are found to be associated 
with cancer or other disease are seen within chromosomal fragile regions resulting in sequence 
amplification or deletion. As sarcomas are highly heterogeneous in nature, it is very difficult to 
validate sarcoma diagnosis. So for proper diagnosis, prognosis and therapeutic intervention of 
different sarcomas miRNA signature plays an important role.
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OBJECTIVES 
Objective 1:
Microarray expression analysis in fibrosarcoma to identify set of differentially expressed 
mRNAs and miRNAs.
Objective 2:
miRNA and mRNA interaction map and target prediction for differentially expressed sets of 
miRNAs and mRNAs of fibrosarcoma.
Objective 3:
Identification of a novel miRNA–mRNA target pairs involved in fibrosarcoma and experimental 
validation by qRT-PCR in HT-1080 cell lines.
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MATERIAL METHODS
1) Gene Expression Data:
For conducting genome wide analysis of mRNA and miRNA from normal and diseased 
sample in fibrosarcoma and in order to study and differentiate between different expression 
pattern for diagnosis and therapeutic mechanisms, the gene expression data is taken. 
  Gene Expression Omnibus is a data base from where the gene expression data were 
retrieved. The GEO is a common data storage supporting MIAME submissions that collects and 
distributes freely next generation sequencing, microarray and different forms of high throughput 
functional genomic data which is submitted by the scientific community. Thus GEO data base is 
the combination of “geo” that is spatial data with “data base” that is data repository in order to 
create a central data repository for spatial data storage and management. In order to provide help 
to users query and download experiments and in order to collect the gene expression profile 
stored in GEO, a collection of web based interfaces and applications are available. Raw 
microarray data found in GEO database have images that can be converted into gene expression 
matrices where rows represent genes and column represent various samples. In order to extract 
any biological process information analysis of matrices can be done. Platform generally 
describes list of features on array. 
The mRNA and miRNA expression data of the cancer fibrosarcoma and corresponding 
normal control fat sample was taken for our analysis.
PLATFORMS taken:
Expression Data GEO accession Title
mRNA GPL96 [HG-U133A] Affymetrix Human Genome U133A Array 
miRNA GPL8179 Illumina Human v2 MicroRNA expression beadchip
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Samples taken:
Expression Data GEO accession Title
mRNA GSE21122 Whole-transcript expression data for soft-tissue sarcoma 
tumors and control normal fat specimens
miRNA GSE36982 MicroRNA profiling of primary high-grade soft tissue 
sarcomas and control normal fat
2) Microarray analysis of gene Expression Data:
A) Retrieval of mRNA and miRNA gene expression data:
 All samples of fibrosarcoma and normal control fat ( i.e. all GSMs) present in the GSE were 
taken for analysis
 The details of number of samples taken for mRNA and miRNA expression analysis are given in 
Table 3.
 The data were taken in multiples to reduce error rate. 
 The raw files were downloaded in .CEL format.
 Then the files were unzipped, extracted and renamed as control and test for mRNA and miRNA 
accordingly.
Table 3. Number of samples taken for mRNA and miRNA expression analysis
Expression data Sarcoma No. of samples
mRNA MFH:Myxofibrosarcoma 31
mRNA Normal fat 9
miRNA Myxofibrosarcoma 8
miRNA Normal fat 2
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B) Analysis of Gene Expression Data:
  Agilent’s GeneSpring GX 12.6 software is used for gene expression analysis. This software is a 
powerful microarray expression data analysis tool for fast visualization and analysis of different 
microarrays (gene, miRNA, exon, genome copy number, etc). Class of transcripts showing 
expression pattern which are correlated with experiment variables are identified by using this 
software. Thus mainly for fulfilling the needs of biologists this tool is designed.
     Performing work in GeneSpring GX 12.6 is organized into projects. In a project a number of 
experiments are involved and again an experiment is composed of samples that are data sources. 
Samples are grouped as test and control and interpretations are done based on the defined 
parameters of sample grouping and finally analysis involves a number of statistical steps and 
corresponding results.
   All information on array design along with biological information is found in Genespring GX. 
So for each new array type which is to be analyzed, a new technology must be installed initially. 
Technologies created include affymetrix for standard arrays, Agilent and Illumina.
   In GeneSpring following steps are used:
I. For gene expression analysis :
        In order to minimize the systematic non-biological differences to reveal true biological 
differences, normalization of data was done, after which profile plot of normalized intensity map 
values are obtained. To standardize each chip for cross comparison, data is normalized to 75th
percentile of signals intensity. The main purpose is to eliminate redundancy and make sure that 
the data makes sense with minimum number of entities.
  A new experiment was created for analysis of gene expression. The experiment type should be 
specified as Affymetrix. Workflow selected was Guided Workflow.
  Using choose sample option the unzipped samples (both sarcoma and normal fat) were 
uploaded to the experiment in GeneSpring from the saved location in the system. Experimental 
grouping was done to define samples as test and control and assigning a parameter name (e.g. 
Average).
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By using Filter Probsets by Errors, quality control of samples was done. This was done on 
the raw signal values of all the entities.  For filtering , cut off was set at 20 percentile of all 
intensity values and a profile plot of filtered entities was generated. Using the normalized signal 
values and grouped samples by active interpretation box whisker plot is generated.
Significance analysis depending upon experiment grouping, was done by performing T-Test 
unpaired analysis as 2 groups are there that is control and test along with replicates.
For computing p-values Benjamini-Hochberg FDR algorithm multiple testing correction was 
used. The p-value cut off taken was ≤0.05. This reduces the number of false positives or false 
discovery rate. This multiple testing correction is least stringent. Fewer chances of false negative 
genes are there. A p-value of ≤0.05 is taken as significant.
For identifying differentially genes among the cancerous and non-cancerous samples which are 
expressed above a definite threshold, fold change analysis is done. It gives the absolute ratio of 
normalized intensities between the average intensities of grouped sample. Fold change cut off is 
taken ≥2.0.
Further 2D hierarchical clustering of the genes expressed >2.0 fold was carried out taking 
average linkage to classify the cancerous and normal control samples and a heat map was 
generated using CLUSTER 3.0 and JAVA tree view. Hierarchical clustering method arranges 
gene in a tree structure based on their similarity. If the items are similar to each other then they 
are connected by short branches and if it is dissimilar then it is connected by long braches.
Genes expressed greater than 2 fold were exported from GeneSpring along with normalized 
signal values, gene symbols, entrez gene IDs etc. The entity list was exported as .txt file and later 
opened with excel for further analysis.
II. For miRNA expression analysis :
miRNA expression analysis was carried out in the same project of GeneSpring, but in a new 
experiment. miRNA specific platform i.e Illumina was chosen and further steps of analysis were 
same as that of mRNA expression analysis
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The miRNAs differentially expressed greater than 2 fold between the normal and cancerous 
samples were exported for further analysis.
C) Analysis of Gene and miRNA list:
With the aim of finding a probable oncogene the gene ontology analysis was carried out 
for the genes up-regulated using web based gene set analysis tool kit. Genes with functions and 
probable role in metastasis was focused on.
Similarly with the aim of finding a probable tumor suppressor which might be targeting 
the oncogene of our interest the list of down-regulated miRNAs involved in fibrosarcoma was 
analyzed for its fold change value and function from literature study.
3) Target interaction map through Magia2 Software:
The integrated analysis of in-silico target prediction of miRNA and gene expression data for 
reconstruction of post transcriptional regulatory networks is performed by using software called 
Magia2. Due to different levels of regulation and highly interconnected networks of regulatory 
elements and their interaction, gene expression profile is resulted. Magia is a web based tool 
which is designed in order to cope with low sensitivity of target prediction algorithms by 
exploring the interaction of target prediction with miRNA and gene expression profiles. In order 
to improve detection of miRNA-mRNA for in-silico target prediction magia generates a highly
interconnected network of miRNA, mRNA, transcription factors. 
The gene expression and miRNA expression data were uploaded and submitted using 
Pearson correlation method analysis which aims to display the target interaction map for 
matched miRNAs and gene expression data.
From the interaction map one gene and one miRNA pair was selected based upon their 
regulation and association with cancer for further validation by qRT-PCR. This pair has not been 
validated experimentally in any cancer system before.
4) RNAhybrid study:
RNAhybrid was run to study interaction among the chosen gene and miRNA pair. It is a tool for 
finding the minimum free energy of hybridisation of a long and a short RNA.
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5) Experimental validation :
Human fibrosarcoma cell line HT-1080 was obtained from National Centre for Cell Science, 
Pune, India. The media used for culturing the cell is DMEM (Dulbecco’s Modified Eagle’s 
Medium) with FBS (Fetal Bovine Serum) from HIMEDIA and 1% antibiotic solution. The 
culture flask containing the cell line is kept in CO2 maintained at 5%. By utilizing medium, the 
color of medium changes from red to orange and then to pale yellow because of change in pH of 
medium. 
CELL CULTURE:
I. Reviving of stored cells 
For reviving cells they are first thawed by drastically reducing the stored cells temperature from -
80oC to 37oC in a water bath to avoid formation of crystals. 5ml of DMEM was taken in a T25 
flask and the thawed cell specimen is pipetted into the flask. The flask was swirled gently in 
order to mix the cells with medium. Sometime removal of DMSO is necessary especially for 
specimen cells, primary cells and sensitive cells types. For such cell types, pipette the thawed 
cell specimen into a sterile centrifuge tube containing medium. Centrifuge at 1500rpm for 5min, 
aspirate the supernatant, then re-suspend the cells in fresh medium. Cells were incubated 
overnight under their usual growth conditions. 24hrs later the cells were checked for their 
adherence to the flask and the growth medium was replaced. The cells are grown in a flask until 
they are confluent enough or their medium has been utilized and they are ready for sub-culture. 
II. Trypsinizing cells:
Trypsinization is a technique that uses the proteolytic enzyme trypsin in order to detach adherent 
cells from the surface of a cell cultured vessel. This procedure is preferred whenever the cells 
need to be harvested and sub-cultured. For trypsinization the medium was aspirated and 
discarded. Cells were washed with 1X PBS. 1ml 1X trypsin EDTA solution was added. The flask 
was placed in a co2 incubator at 37oc for 1 to 2 minute or until all cells were detached. Flask was 
removed from incubator and firmly taped with palm of hand to assist detachment. Once all the 
cells dislodged, cells were re-suspended in a growth medium containing serum. Use medium 
containing the same percentage of serum as used for growing the cells. The serum inactivates 
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trypsin activity. Then cells were pippetted gently up and down and transformed to an RNAase 
free glass or polypropylene centrifuge tube and then centrifugation done at 1500rpm for 5 
minute. Then the supernatant was aspirated completely and the cells again re-suspended in 1X 
PBS and were counted. The appropriate no. of cells were taken for isolation of RNA by again 
pelleting the cells and removing PBS. 
RNA isolation:
 mRNA isolation :
For mRNA isolation QIAGEN kit is used.
1) First at a maximum of 1 × 107 were harvested then appropriate volume of buffer RLT was 
added.
2) To the lysate, 1 volume of 70% ethanol was added and mixed well by pipetting. Immediately 
proceed to step 3.
3) 700µl of sample including any precipitation was transferred to an RNeasy mini spin column 
placed in 2ml supplied collection tube.Then the lid was closed and centrifuged for 15 sec at ≥ 
8000xg.Then flow through was discarded.
4) To RNeasy spin column 700µl of RW1 was added. Then the lid was closed and centrifuged 
for 15 sec at  8000xg.Then flow through was discarded.
5) To RNeasy spin column 500µl of RW1 was added. Then the lid was closed and centrifuged 
for 15 sec at ≥ 8000xg.Then flow through was discarded
6) To RNeasy spin column 500µl of RW1 was added. Then the lid was closed and centrifuged 
for 2 minute at ≥ 8000xg. 
7) In a new 1.5ml collection tube the RNeasy spin column was placed. 30-40µl RNase free water 
was added directly to spin column membrane. Then the lid was closed and centrifuged for 1 
minute at ≥ 8000xg in order to elute RNA.
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8) If the expected RNA yield is more than 30µg, then the step-7 was repeated using another 30-
50µl of RNase free water or using the elute from step-7.The collection tube were reused from 
step-7.
9) By using Eppendorf NanDrop, the purity and yield of RNA was measured. It is a cuvette free 
spectrophotometer eliminating the need for other sample containment device and also allows for 
clean up in seconds. 1µl of sample can be measured with this instrument with high accuracy and 
reproducibility. 1µl of sample was pipetted onto the end of a fiber optic cable. A second fiber 
optic cable is then brought into contact with the liquid sample causing the liquid to bridge the 
gap between the fiber optic ends. A pulsed xenon flash lamp provides the light source and 
spectrometer utilizing a linear CCD array is used to analyze the light after passing through 
sample. The instrument is controlled by based software and the data is logged in an archive file 
on PC.
 MicroRNA isolation :
1) Cells were collected after trypsinization. And then wash with PBS and cells pellets were 
collected, then it was kept in ice for some minute.
2) PBS was removed, 600 µl lysis or binding solution was added.
(If the cells are 100s in number -300 µl)
(if cells are 1000s in number -600 µl)
3) Now the solution was vortex vigorously to make homogenous lysate.
4) 1/10th (for 600/10=60 µl) of microRNA  homogenate additions was added to cell, then mixed 
well by vortexing or inverting several times , then kept on ice for 10 minute.
5) 1 volume of Acid phenol chloroform that is equal to lysate volume is added before addition of 
miRNA homogenate, then vortexed for 30 to 60 sec in order to mix then it was centrifuged for 5 
min at 10,000 g at room temperature to separate aqueous   and organic phases. (After 
centrifugation the interphase should be compact if it is not then centrifugation is repeated) 
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6) Aqueous phase is carefully removed without disturbing the lower phase and transferred into a 
new tube.
7) 1.25 volume of room temperature 100% ethanol was added to aqueous phase.
8) A filter cartridge was placed into one of the collection tubes, then it was mixed by pipetting 
then centrifuged for 15 sec at 10000 rpm, then flow through was discarded until all the lysate is 
through.
9) 700µl of miRNA wash solution I was added to filter cartridge and then centrifuged for 5 to 10 
sec and then flow through was discarded.
10) 500 µl of wash solution 2/3 centrifuged it for 5 to 10 sec. Again repeat it with 500 µl of wash 
solution 2/3.
11) After discarding the flow through from last wash, the filter cartridge was replaced same in 
collection tube and assembly was undergo spinning for 1 min to remove residual fluid from 
filter.
11) Filter cartridge was transferred into a fresh collection tube .100µL of pre heated (95oC) 
elution buffer or nuclease free water was applied ,cap was closed and it undergo spinning for 20 
to 30 sec at maximum speed to remove microRNA.
12) The elute was collected and stored at -20oc or below.
cDNA Synthesis:
mRNA cDNA synthesis: cDNA Synthesis was carried out using Super Script First Standard 
Synthesis System for RT-PCR by invitrogen using oligo dT primer.
1) Each of the components were mixed and centrifuged briefly before use.
2) For each reaction the following in a sterile 0.2 or 0.5 tube was combined.
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Components Amount
RNA 4 µl
10mM dNTP mix 1 µl
Primer(0.5µg/µl oligo (dT)12-18OR 2 µM gene 
specific primer)
1 µl
DEPC treated water 4µl
3) The RNA/Primer mixture was incubated at 65oc for 5 minute and then placed on ice for at 
least 1 minute.
4) Following 2X reaction was prepared in a separation tube by adding each component in the 
indicated order.
Component 1RXn 10RXn
10X RT buffer 2 µl 20 µl
25Mm Mgcl2 4 µl 40 µl
0.1MDTT 2 µl 20 µl
RNase outTM(400/µL) 1 µl 10µl
5) To each RNA/Primer from step3, 9µl of 2X reaction mixture was added, mixed gently and 
collected by a brief centrifuge.
6) It was incubated at 42oc for 2 minute.
7)1µl of superscript TM II RT was added to each tube.
8) It was incubated for 50 minute at 42oc.
25
9) The reaction was terminated at 70oc for 15 minute and then chilled on ice.
10) By brief centrifugation the reaction was collected. To each tube 1 µl of RNase H was added 
and incubated at 37oc for 20 minute and then the reaction was used for PCR immediately.
MicroRNA cDNA synthesis: miRNA cDNA synthesis was carried out using NCode™ miRNA 
First-Strand cDNA Synthesis Kit.
1) 100 to 1µg of optimal RNA was taken.
2) DNase I may be used to eliminate genomic cDNA contain.
3) Undiluted cDNA are to be used for qRT-PCR.
4) The following reaction volume may be scaled as needed upto 100µl .For single reaction , 
combine the following components in a tube on ice. For a multiple reactions a master mix is 
prepared without RNA.
Components Amount
5X reaction mix 4 µl
10X superscript 2 µl
Total RNA 2.5 µl
DEPC water 11.5µl
5) The tube was capped then gently vortexed to mix and centrifuge then briefly.
6) The tube was then incubated at 37oc for 60 minute, terminated at 95oc for 5 minute and then 
hold the reaction at 4oc until use.
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SEMI-QUANTITATIVE RT-PCR ANALYSIS:
To assess the quality of the cDNA formed and to find the annealing temperature of the primer a 
semi-quantitative gradient PCR was carried out. The cycling conditions were 95 oC for 5 min for 
initial denaturation, 95oC for 30secs for denaturation, 57oC-60.6 oC for 60 sec as the range for 
annealing temperature, 72 oC for 1 min for final extension temperature, repeated 37 times. 
QUANTATIVE RT-PCR ANALYSIS:
In qRT-PCR florescence signal is continuously collected from one or more polymerase chain 
reactions over a range of cycles. Thus florescence signals from each reaction are converted into a 
numerical value for each sample. In order to bind DNA florescent maker is used. Thus during the 
reaction as the number of copies increase, so the florescent intensity increases. SYBR green is a 
intercalating florescent dye, and it is the simplest and cheapest way in order to monitor a PCR in 
real time. The SYBR green dye florescence only on binding to double stranded DNA. Using dye
has one disadvantage, which is lack of specificity.
From primer bank Database (Harvard) the gene specific primer sequence were obtained and the 
primers were synthesized by Sigma. All the primers were desalted. 
Procedure of mRNA qRT-PCR:
  In order to perform PCR by using RNA as a starting template, it must first have to transcribed 
into cDNA in a reverse transcription reaction, in which cDNA is act as template for RT-PCR 
with gene specific primres (Table 4.).
Table 4. Primer name and sequence with length and its amplicon size
Gene Sequence Amplicon size
ACTB F- F-CATGTACGTTGCTATCCAGGC 250
R- R-CTCCTTAATGTCACGCACGAT
p15PAF F- F-ATGGTGCGGACTAAAGCAGAC 123
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R- R-CCTCGATGAAACTGATGTCGAAT
miRNA-429 F-CGGCGTAATACTGTCTGGTAAAACCGT 22
In Eppendorf Masterplex Real Time PCR, RT-PCR was carried out. Primer concentration was 
normalized and gene specific forward and reverse primer pair was mixed. Each primer that is 
forward and reverse primer concentration in mixture was 3.5µl.
a) Now the experiment was ready and the following PCR program was made on. A copy of 
the set up file was saved and all other PCR cycles were deleted. Threshold frequency was 
taken was 33%. The temperature cycle were taken as follows:
Stage Temperature(oc) Time Cycle
Stage 1 95 20 sec 1
Stage2 95
55
68
15 sec
15 sec
20 sec
40
Stage3 95
60
95
15sec
15sec
15sec
1
b) cDNA was diluted to 1:20 ratio concentration and  then primer was added.
c) 10µl of a real time PCR reaction volume was made.
d) In each optional tube as the following mixture was made follows.
SYBR Green Mix(2x) 35µl
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cDNA stock(cDNA:dH2O[1:20]) 40 µl
Primer pair mix(3.5µl each primer) 7 µl
e) With the help of in-built software , the RT-PCR result was analyzed.
f) The tubes were removed from the machine, after PCR is finished.
Procedure of microRNA-qRT-PCR:
a) Undiluted cDNA was used for quantification.
b) 10µl of a real time PCR reaction volume was made.
In each optional tube as the following mixture was made follows:
SYBR Green Mix(2x) 5 µl
cDNA stock 2µl
DEPC H2O 2.6 µl
Forward primer 0.2 µl
Reverse Primer 0.2  µl
c) With the help of in-built software, the RT-PCR result was analyzed.
d) The tubes were removed from the machine, after PCR is finished.
RESULTS AND DISCUSSION
Microarray Analysis
 mRNA Expression Analysis: 1068 differentially expressed
Myxofibrosarcoma and the control normal fat samples
and 510 genes were down-regulated. 
relatedness among the samples as
clustered together (Fig 4). 
      
Fig 4: Hierarchical clustering of MFS and normal fat samples
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genes (DE) were obtained between 
. Of these 558 genes were up
Hierarchical clustering of the DE genes showed 
all control samples clustered together and all sarcoma samples 
-regulated 
the 
 microRNA Expression Analysis
Myxofibrosarcoma and the control normal fat samples. Of these 51 miRNAs were up
and 27 miRNAs were down-regulated.
relatedness among the samples as all control samples clus
clustered together (Fig 5)
Fig 5: Hierarchical clustering of differentially expressed m
GO analysis: GO analysis was carried out using a 
genes involved in different biological processes.
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: 77 differentially expressed miRNAs were obtained between 
Hierarchical clustering of the DE miRNAs showed the 
tered together and all sarcoma samples 
iRNAs  
web based gene set analysis tool 
As we wanted to find a gene involved in the 
-regulated 
kit to find the 
metastasis of sarcomas we mainly focused
which leads to metastasis (Fig 6).
Fig 6: GO analysis of differentially expressed genes in fibrosarcom
From the genes involved in cell proliferation, genes which were up
for further analysis for interaction with miRNAs which are down
tumor suppressive role.  
Target interaction map analysis
miR-429 and 4 genes by the miR
Fig 7: Interaction map of mRNA and miRNAs involved in fibrosarcoma
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on the genes involved in the cell proliferation
a
-regulated were considered 
-regulated and have a probable 
: Target interaction map resulted in 36 genes targeted by the 
-375.
Metabolic Process
Biological Regulation
Cellular component organization
Response to stimulus
Multicellular Org process 
Developmental Process
Cell Communication
Localization
Cell Proliferation
Reproduction
Death
Growth
Multi Organism Process
process 
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From the two miRNAs obtained from the target interaction map, miR-429 was selected based on 
its role in cell proliferation and migration of cancer cells as obtained from extensive literature 
study and high fold down-regulation obtained in all sarcomas according to microarray data. This 
showed that it might act as a tumor suppressor in the sarcomas. From the 36 genes it targeted we 
selected 10 genes based on their fold change and literature analysis for probable role as an 
oncogene.
RNAhybrid
RNAhybrid interaction was carried out using the miR-429 and all 10 genes and the p15PAF gene 
targeted by the hsa-miR-429 was selected. This gene and miRNA pair was selected based on the 
q-value of the pair which was found to be lowest from the Magia2 interaction analysis. Other 
factors considered for choosing the pair was their fold change information from microarray data, 
extensive literature study on their probable role in other cancers and finally the lowest MFE 
(minimum free energy) value found among all the 10 pairs and a good 8 mer binding.
Interaction between p15PAF (3/UTR) and miR-429 using RNAhybrid
In this result we found that the p15PAF form hybrid with has-miR-429 at position 22067 and 
eight nucleotide pairing (8 mer) was found in the RNA hybrid.
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Experimental Validation:
RNA Isolation
260/280 ratio: This indicates the absorbance of RNA and DNA at 260 nm and 280 nm
respectively. It is used to access the purity of DNA and RNA. Approximately 1:8 ratio is 
generally expected and accepted as “pure” for DNA and approximately 2.0 ratio is as “pure” for 
RNA. In either case, if the ratio is significantly lower it may indicate the presence of phenol, 
protein or other contaminants that absorb strongly at or near 280nm.
260/230 ratio: It is used as a secondary measure of nucleic acid purity. The 260/230 
values for “pure” nucleic acid is generally higher than the respective 260/280 values. Expected 
260/230 values are normally lies in the range of 2.0-2.2. If the ratio is significantly lower than 
the expected ratio, then it indicatse that contaminants absorbing at 230 nm is present.
Here from 2 samples we got following result:
HT1080 mRNA conc. = 254.1µg/ml H1080 miRNA conc = 400.1µg/ml
At (260/280) = 2.07 At (260/280) = 2.00
At (260/230) = 1.79 At (260/230) = 2.01
Semi-quantitative PCR
A semi quantitative gradient PCR was carried out to assess the annealing temperature of the gene 
p15PAF. Also we could know the quality f the cDNA prior to setting up qRT-PCR and get an 
idea about the quantitative amount of the gene with respect to beta actin and thus called semi-
quantitative (Fig 8). 
                                 
Fig 8: Result of Semi-quantitative PCR
qRT-PCR:
The qRT-PCR program used 59º
p15PAF was best at that temperature
Fig 9: Cycle temperature and time for qRT
1- 60.6
2- 60.0
3- 59.1
4- 57.9
5- 57.0
6- Blank
7- 1000bp Ruler
8- Blank
9- 60.6
10- 60.0
11- 59.1
12- 57.9
13- 57.0
<-----------
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C as annealing temperature as the amplification for ACTB and 
(Fig 9). 
-PCR
Β-Actin---->              <-----------p15PAF------>
 qRT-PCR melting curve analysis 
p15PAF and ACTB as only a single peak was obtained for the respective genes. There was no 
non specific amplification (Fig 10 )
Fig 10: Melting temperature curve of p15PAF with respect to ACTB
                        
Fig 11: Result of qRT
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showed a single amplification product was formed for the 
.
-PCR analysis of p15PAF gene and miR
ACTB p15PAF
HT-1080
-429
                          
                              Fig 12: qRT-PCR analysis of p15PAF gene and miR
From qRT-PCR analysis of p15PAF gene, a fine melting curve of p15PAF is observed in 
comparison to the control β-actin
ACTB is 89.2 ºC. As the samples of gene were taken in triplets, 3 peaks of p15PAF positioned at 
one place were observed. The quantification of p15PAF w
expression of p15PAF. Similarly the relative quantification of miR
snRNA shows a lower expression of miRNA
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-429 
(Fig 11.). The melting temperature of p15PAF is 84.8ºC and 
ith respect β-actin shows lower
-429 with respect to U6 
-429 (Fig 12).
U6 miR-429
HT-1080
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CONCLUSIONS
Our study aimed at recognition of novel mRNA-miRNA target pairs which is considered 
to play important role in fibrosarcoma through an mRNA-miRNA interaction map analysis of 
microarray data along with experimental validation of selected set of mRNAs. From mRNA 
microarray expression analysis, we found 1068 differentially expressed genes between 
Myxofibrosarcoma and the control normal fat samples. Again from miRNA expression analysis, 
77 differentially expressed miRNAs were obtained between Myxofibrosarcoma and the control 
normal fat samples. Of these, 51 miRNAs were up-regulated and 27 miRNAs were down-
regulated. From target interaction map we have chosen one pair, hsa-miR-429-p15PAF which 
was seen to be novel target pair. The quantification of p15PAF with respect β-actin shows lower
expression of p15PAF. Similarly the relative quantification of miR-429 with respect to U6 
snRNA shows a lower expression of miRNA-429. As we didn’t have control cell line we 
couldn’t go for relative gene expression analysis of the gene and miRNA. Further analysis of the 
expression of the gene and miRNA has to be carried out to establish their role as an oncogene 
and a tumor suppressor miRNA respectively. Further analysis of their role in metastasis has to be 
carried by their over-expression/ inhibition and carrying out using different cell proliferation 
assays like MTT assay and migration assays like wound healing and scratch assay. These assays 
will establish their role as an oncogene and tumor suppressor miRNAs. Further analysis can 
prove whether hsa-miR-429 and p15PAF can be considered to be novel target pair which will be 
playing a role in the metastasis of fibrosarcoma. 
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FUTURE PROSPECTIVES
The effectiveness of miRNA based fibrosarcoma therapy can be a land mark in fibrosarcoma 
studies. Recognition of genome wide targets of miRNAs is a promising approach which can be 
experimentally validated to have a role in fibrosarcoma. Henceforth, with a better prospective 
about the gene networks and their cellular pathways regulated by miRNAs, the elucidation of 
fibrosarcoma pathogenesis and therapeutics can be facilitated. Furthermore, experimental 
validation of hsa-miR-429- p15PAF through Luciferase Reporter Assay or any other molecular 
techniques will strengthen the foundation of miRNA – mediated regulation in fibrosarcoma. 
Subsequent analysis of this novel miRNA-target pair will enhance our understanding to 
manipulate pathways for treatment of fibrosarcoma through microRNA mediated therapeutics.
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